An observational study in Multiple Sclerosis, sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia. Completed at 1 site in Argentina. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2013-10-22.
Sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · Observational
Recently, it has been shown that salt (ClNa, sodium chloride) can modulate the differentiation of human and mouse TH17 cells. Indeed, mice feed with high sodium diet were described to develop more aggressive course of EAE (Experimental Autoimmune Encephalitis).
However, the role of sodium intake in MS has not been investigated. In this study we investigate the effect of sodium intake in Multiple Sclerosis (MS) clinical and radiological activity.
3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.
This study's enrollment of 132 is above the median of 100 across 1,016 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
A total of 70 patients with relapsing-remitting MS according to McDonald criteria1 were recruited from the MS clinic at FLENI by attending neurologists. A second group of 52 relapsing-remitting MS patients was recluted later.
Exclusion Criteria:
MS patients
Exacerbation rate
Number of disease relapses during follow up time according to salt consumption
Time frame: 2 years
Radiological activity
Number of new lesions in MRI
Time frame: One year
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia